Clinical Trials Logo

HER2 Expressing Solid Tumors clinical trials

View clinical trials related to HER2 Expressing Solid Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT02386501 Completed - Clinical trials for HER2 Expressing Solid Tumors

Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b, multicenter, open-label, dose-escalation study designed to estimate the maximum tolerated dose (MTD) and determine the recommended Phase 2 dose (RP2D) of ADXS31-164. Once the RP2D has been selected, up to 4 expansion cohorts will be evaluated.